Document is current

Article History

Received: 18 September 2024

Accepted: 4 December 2024

First Online: 11 February 2025

Declarations

:

: Not applicable.

: Not applicable.

: AM is an employee of Berry Consultants, a consulting company that specialises in the design, conduct, oversight, and analysis of adaptive and platform clinical trials. MPC reports grants from the Canadian Institutes of Health Research during the conduct of the study and is supported by the Fonds de Recherche du Québec – Santé; personal fees from GEn1E Lifesciences and from Nomic Bio as a member of the scientific advisory board; as well as honoraria from AstraZeneca, Takeda, Merck, and Pfizer; research support from Cidara therapeutics, from Scynexis, Inc.; and from Amplyx Pharmaceutics during the conduct of the study but outside the submitted work. MPC is the co-founder of Kanvas Biosciences, Inc. and owns equity in the company. MPC has pending patents, including (i) methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling and (ii) methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending. DLP reports that he is a consultant to the AMR Action Fund and CARB-X. RJL is the senior medical scientist and an employee of Berry Consultants, LLC, a statistical consulting firm that specialises in the design, implementation, conduct, oversight, and analysis of adaptive clinical trials, including platform trials. Where relevant, views contained within this commentary represent the authors’ own and not those of the NIHR or the UK Department of Health and Social Care.